• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

ESMO: Bristol Myers' Opdivo chalks up bladder cancer win. But a rival combo casts long...

cafead

Administrator
Staff member
  • cafead   Oct 22, 2023 at 06:12: PM
via Bladder cancer hasn’t been the easiest tumor type to tackle for immunotherapies. Bristol Myers Squibb has found success here with its Opdivo, but the win was overshadowed by competitor data.

article source
 

<